The FDA has accepted Regeneron's Biologics License Application for garetosmab to treat fibrodysplasia ossificans progressiva, granting Priority Review with a target action date of August 2026. The application is supported by Phase 3 OPTIMA trial data.
The FDA has accepted Regeneron's biologics license application for garetosmab with priority review, targeting fibrodysplasia ossificans progressiva. A decision is expected by August 2026 based on Phase 3 trial data showing significant reductions in new bone lesions.
The FDA approved pembrolizumab in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1).
The FDA has accepted for Priority Review Regeneron's biologics license application for garetosmab to treat adults with fibrodysplasia ossificans progressiva, with a target action date of August 2026.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07531472 |
Outcome of Hyaluronic Acid Gel Versus Petroleum Jelly in Treatment of Epistaxis |
NOT_YET_RECRUITING | NA |
| NCT07511192 |
The Efficacy of Local Application of B-sitosterol Versus Vasline in Cases of Idiopathic Epistaxis |
NOT_YET_RECRUITING | PHASE4 |
| NCT06985108 |
Comparison of Nasal Endotracheal Tube and Spiral Tube for Nasotracheal Intubation in Pediatric Patients |
COMPLETED | NA |
| NCT06906861 |
Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal |
COMPLETED | |
| NCT06836102 |
Usage of Orange Peel Extract in Management of Epistaxis |
NOT_YET_RECRUITING | NA |
| NCT06657053 |
Risk Factors of Epistaxis Recurrence in Adults |
NOT_YET_RECRUITING | |
| NCT06259292 |
Comprehensive HHT Outcomes Registry of the United States (CHORUS) |
RECRUITING | |
| NCT05343650 |
NOVAPAK Nasal Packing in Shellfish Allergic Patients |
UNKNOWN | PHASE4 |
| NCT05334017 |
Xylometazoline and Cocaine for Nasal Vasoconstriction |
COMPLETED | PHASE4 |
| NCT05281952 |
Medico-economic Evaluation of Management Strategies for Severe Epistaxis |
RECRUITING | NA |
